(Nasdaq: CNSY) (“Cerenome” or the “Company ”), today announced the commercial launch of two new cerebrospinal fluid (CSF)-based molecular profiling tests, available to health care professionals in the ...
ATH434 50 mg significantly slowed functional decline in MSA by approximately 52% versus placebo on the 11-item UMSARS at Week 52 with CSF NfL as ...
The analysis also showed that a biomarker of disease severity predicted how quickly patients declined. ... Read More The post Alterity’s biomarker-adjusted Phase 2 analysis shows ~52pc slowing of MSA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results